Clinical Scorecard: Gender-Differentiated Impact of Long-Term Proton Pump Inhibitor Use on Bone Density and Microarchitectural Integrity
At a Glance
Category
Detail
Condition
Bone fragility associated with chronic proton pump inhibitor (PPI) use
Key Mechanisms
Chronic PPI use may degrade trabecular bone microarchitecture and affect bone mineral density (BMD), with sex-specific differences
Target Population
General adult population using PPIs chronically, stratified by sex
Care Setting
Outpatient clinical settings and population health surveillance
Key Highlights
Chronic PPI use is associated with degraded trabecular bone quality (lower trabecular bone score, TBS) and reduced BMD in men but not in women.
The negative impact on bone microarchitecture in men remains significant even after adjusting for BMD, indicating effects beyond bone density alone.
Previous studies show conflicting results on PPI effects on BMD; this study highlights the importance of assessing bone quality via TBS, especially in men.
Guideline-Based Recommendations
Diagnosis
Consider assessing trabecular bone score (TBS) alongside bone mineral density (BMD) in chronic PPI users, particularly men, to evaluate bone quality.
Use lumbar spine dual-energy X-ray absorptiometry (DXA) scans to measure BMD and calculate TBS for bone health assessment.
Management
Monitor bone health in patients on long-term PPI therapy, especially male patients, to identify early signs of bone microarchitectural degradation.
Evaluate the risk-benefit ratio of continued PPI use in patients at risk for osteoporosis or fractures.
Monitoring & Follow-up
Regularly monitor bone density and microarchitecture in chronic PPI users, with sex-specific considerations.
Adjust monitoring frequency based on individual risk factors such as age, sex, and duration of PPI use.
Risks
Chronic PPI use increases risk of bone fragility and fractures, particularly in men.
Potential long-term adverse effects of PPIs include increased risk of enteric infections, pneumonia, gastric cancer, and bone fractures.
Patient & Prescribing Data
Adults from the general U.S. population using PPIs chronically, including both men and women.
Men on chronic PPI therapy show statistically significant reductions in TBS and BMD at lumbar spine, total hip, and femoral neck; women do not show significant changes.
Clinical Best Practices
Incorporate sex-specific evaluation when assessing bone health in chronic PPI users.
Use TBS as a complementary tool to BMD for a more comprehensive assessment of fracture risk.
Be vigilant for bone health deterioration in male patients on long-term PPI therapy even if BMD appears normal.
Educate patients on potential bone health risks associated with prolonged PPI use and consider alternative therapies if appropriate.
